![Matthew Parris](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Matthew Parris formerly worked at Aegerion Pharmaceuticals, Inc., as Director-Clinical Operations, Inovio Pharmaceuticals, Inc., as Director-Clinical Operations, and Eleison Pharmaceuticals, Inc., as Vice President-Clinical Development.
Mr. Parris received his undergraduate degree from Imperial College London.
| Companies | Position | End |
|---|---|---|
| AEGERION PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| INOVIO PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Eleison Pharmaceuticals, Inc.
 Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes clinical stage drug candidates for orphan cancers | Corporate Officer/Principal | - |
| TRAWS PHARMA, INC. | Chief Tech/Sci/R&D Officer | - |
Active
Inactive
Listed companies
Private companies
| Private companies | 5 |
|---|---|
Traws Pharma, Inc.
 Traws Pharma, Inc. BiotechnologyHealth Technology Discovers and develops products for patients with cancer | Health Technology |
Aegerion Pharmaceuticals, Inc.
 Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and commercializes therapies for hyperlipidemia and metabolic diseases | Health Technology |
Imperial College London
 Imperial College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Inovio Pharmaceuticals, Inc.
 Inovio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops synthetic vaccines and immune therapies for cancers and infectious diseases | Health Technology |
Eleison Pharmaceuticals, Inc.
Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes clinical stage drug candidates for orphan cancers | Health Technology |
Select your edition
All financial news and data tailored to specific country editions
